Wegovy is the brand name for the medication semaglutide. It is an injectable prescription medication used for chronic weight management in adults who have obesity or are overweight and have at least one weight-related condition (such as high blood pressure, type 2 diabetes, or high cholesterol).
Semaglutide belongs to a class of medications called glucagon-like peptide-1 receptor agonists (GLP-1 RAs). GLP-1 is a hormone that is naturally released in the body after eating, and it helps regulate blood sugar levels and appetite. By mimicking the effects of GLP-1, semaglutide can help reduce hunger and increase feelings of fullness, leading to weight loss.
Wegovy is typically administered once a week as a subcutaneous injection (under the skin). It should be used in conjunction with a reduced-calorie diet and increased physical activity. The recommended dosage and treatment duration should be determined by a healthcare professional.
In clinical trials, Wegovy has demonstrated significant weight loss results. It is important to note that this medication is intended for individuals who have a body mass index (BMI) of 30 or higher or a BMI of 27 or higher with at least one weight-related condition.
As with any medication, Wegovy can have side effects. Common side effects may include nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue. It is crucial to discuss potential risks, benefits, and side effects with a healthcare provider before starting Wegovy.
Please note that my knowledge cutoff is in September 2021, and there may be more recent developments or information about Wegovy. It is always advisable to consult with a healthcare professional for the most up-to-date and personalized advice regarding any medication.